Frankfurt am Main, Germany

Maria Mendez Perez

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 12.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2021

where 'Filed Patents' based on already Granted Patents

1 patent (USPTO):

Title: Maria Mendez Perez: Innovating Insulin Conjugates in Frankfurt am Main

Introduction: Maria Mendez Perez is a notable inventor based in Frankfurt am Main, Germany. She has made significant contributions to the field of pharmaceuticals, particularly concerning insulin formulations. With her dedication and innovative spirit, Maria aims to improve the lives of individuals relying on insulin therapy.

Latest Patents: Maria holds a patent for her invention titled "Insulin Conjugates." This groundbreaking invention relates to a conjugate that incorporates a sulfonamide and an active pharmaceutical ingredient, specifically an insulin analog featuring at least one mutation from the parent insulin. The patent details mutations at position B16 and position B25 of the insulin analog, where both are substituted with hydrophobic amino acids. Additionally, her invention introduces a specific sulfonamide formula, showcasing her drive to advance pharmaceutical science.

Career Highlights: Currently, Maria is employed by Sanofi, a leading global biopharmaceutical company. Her role at Sanofi allows her to collaborate with top-tier professionals and contribute to the development of innovative therapeutic solutions. Her patent signifies her expertise in biotechnology, reinforcing her status as a prominent figure in the industry.

Collaborations: At Sanofi, Maria collaborates closely with talented colleagues, including Nils Rackelmann and Laurent Bialy. Together, they share a commitment to pioneering breakthroughs in insulin therapies, fostering a collaborative environment that prioritizes innovation and excellence in research.

Conclusion: Maria Mendez Perez exemplifies the essence of innovation in the pharmaceutical industry. Her work on insulin conjugates marks a significant advancement in drug development, underscoring her role as a key inventor in the field. As she continues to thrive in her career at Sanofi, the medical community eagerly anticipates future contributions that will stem from her innovative research endeavors.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…